中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2010年
12期
885-889
,共5页
肝纤维化,胆汁性%熊去氧胆酸%雌激素
肝纖維化,膽汁性%熊去氧膽痠%雌激素
간섬유화,담즙성%웅거양담산%자격소
Liver cirrhosis,Biliary%Ursodeoxycholic acid%Estrogens
目的 探讨雌激素受体α(ERα)基因多态性对熊去氧胆酸(UDCA)治疗女性原发性胆汁性肝硬化(PBC)疗效的影响.方法 采用聚合酶链反应-限制性片段长度多态性方法 检测65例女性PBC患者ERα基因1号内含子PvuⅡ和XbaⅠ酶切位点多态性.患者每日均予UDCA(13～15 mg/kg,分3次口服)治疗.随访患者临床症状和血清总胆红素(TBil)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(GGT)变化情况,共随访24个月.结果 共60例患者获完整随访资料.XX和PP型患者4项指标均缓慢下降,但至随访结束时未达治疗有效标准.Xx型患者4项指标亦缓慢下降,至随访结束时达治疗有效标准.Pp、pp、xx型患者4项指标均快速下降至治疗有效标准.UDCA治疗PBC有效率75%(45/60).PP、Pp、pp型患者和XX、Xx、xx型患者在UDCA治疗有效组和无效组中的分布差异均有统计学意义(x2=12.13、P=0.003和x2=9.95、P=0.007).Pp、pp、Xx、xx型患者有效率[分别为82.61%(19/23)、80.65%(25/31)、9/14、83.33%(35/42)]高于PP、XX型者(分别为1/6和1/4).结论 PBC患者ERα基因多态性影响UDCA的疗效.
目的 探討雌激素受體α(ERα)基因多態性對熊去氧膽痠(UDCA)治療女性原髮性膽汁性肝硬化(PBC)療效的影響.方法 採用聚閤酶鏈反應-限製性片段長度多態性方法 檢測65例女性PBC患者ERα基因1號內含子PvuⅡ和XbaⅠ酶切位點多態性.患者每日均予UDCA(13～15 mg/kg,分3次口服)治療.隨訪患者臨床癥狀和血清總膽紅素(TBil)、丙氨痠轉氨酶(ALT)、堿性燐痠酶(ALP)、γ-穀氨酰轉肽酶(GGT)變化情況,共隨訪24箇月.結果 共60例患者穫完整隨訪資料.XX和PP型患者4項指標均緩慢下降,但至隨訪結束時未達治療有效標準.Xx型患者4項指標亦緩慢下降,至隨訪結束時達治療有效標準.Pp、pp、xx型患者4項指標均快速下降至治療有效標準.UDCA治療PBC有效率75%(45/60).PP、Pp、pp型患者和XX、Xx、xx型患者在UDCA治療有效組和無效組中的分佈差異均有統計學意義(x2=12.13、P=0.003和x2=9.95、P=0.007).Pp、pp、Xx、xx型患者有效率[分彆為82.61%(19/23)、80.65%(25/31)、9/14、83.33%(35/42)]高于PP、XX型者(分彆為1/6和1/4).結論 PBC患者ERα基因多態性影響UDCA的療效.
목적 탐토자격소수체α(ERα)기인다태성대웅거양담산(UDCA)치료녀성원발성담즙성간경화(PBC)료효적영향.방법 채용취합매련반응-한제성편단장도다태성방법 검측65례녀성PBC환자ERα기인1호내함자PvuⅡ화XbaⅠ매절위점다태성.환자매일균여UDCA(13～15 mg/kg,분3차구복)치료.수방환자림상증상화혈청총담홍소(TBil)、병안산전안매(ALT)、감성린산매(ALP)、γ-곡안선전태매(GGT)변화정황,공수방24개월.결과 공60례환자획완정수방자료.XX화PP형환자4항지표균완만하강,단지수방결속시미체치료유효표준.Xx형환자4항지표역완만하강,지수방결속시체치료유효표준.Pp、pp、xx형환자4항지표균쾌속하강지치료유효표준.UDCA치료PBC유효솔75%(45/60).PP、Pp、pp형환자화XX、Xx、xx형환자재UDCA치료유효조화무효조중적분포차이균유통계학의의(x2=12.13、P=0.003화x2=9.95、P=0.007).Pp、pp、Xx、xx형환자유효솔[분별위82.61%(19/23)、80.65%(25/31)、9/14、83.33%(35/42)]고우PP、XX형자(분별위1/6화1/4).결론 PBC환자ERα기인다태성영향UDCA적료효.
Objective To investigate the effects of estrogen receptor alpha (Erα) gene polymorphism on the efficacy of ursodeoxycholic acid (UDCA) in female primary biliary cirrhosis (PBC) treatment. Methods The polymorphism of Xba Ⅰ and Pvu Ⅱ sites in No. 1 Intron of Erαgene was detected by polymerase chain reaction-restriction fragment length polymorphism in 65 female patients with PBC. The patients were treated with UDCA tablets daily (13-15 mg·kg-1 · d- 1,divided for 3 times oral taking). The variations of patients' serum total bilirubin (Tbil), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyle transpeptidase (GGT) were followed up totally for 24 months. Results Totally the complete follow-up data had been obtained in 60 patients. Four indicators of XX or PP type patients slowly declined till the end of follow-up point still had not reached the effective treatment standard. Four indicators of Xx type patients were also slowly declined, while the effective treatment standard was achieved till the end of follow-up. Four indicators of Pp/pp or xx type patients were rapid declined to the effective treatment standard. The effective rate of UDCA in PBC treatment was 75.0％ (45/60). The distribution difference of Pvu Ⅱ between the UDCA treating effective group and the ineffective group in PP, Pp, pp types patients and XX、Xx、xx types patients was statistic significant (x2 = 12.13、 P = 0.003 and x2 = 9.95 、 P = 0.007 respectively). The distribution difference of Xba Ⅰ between the effective group and the ineffective group with UDCA treatment in XX, Xx and xx types patients was also significant (P ＜0.05). The effective rate of Pp, pp, Xx, xx types patients [82.61％ (19/23)、80.65％ (25/31) 、9/14、83. 33％ (35/42) respectively] was higher than PP and XX types patients (1/6 and 1/4 respectively).Conclusion Erα gene polymorphism influenced the efficacy of ursodeoxycholic acid in treating primary biliary cirrhosis.
